- Home
- ACET vs KORE Comparison
ACET vs KORE Comparison
Compare ACET & KORE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACET
- KORE
- Stock Information
- Founded
- ACET 1947
- KORE 2003
- Country
- ACET United States
- KORE United States
- Employees
- ACET N/A
- KORE N/A
- Industry
- ACET Biotechnology: Pharmaceutical Preparations
- KORE Telecommunications Equipment
- Sector
- ACET Health Care
- KORE Consumer Discretionary
- Exchange
- ACET Nasdaq
- KORE Nasdaq
- Market Cap
- ACET 44.4M
- KORE 42.5M
- IPO Year
- ACET N/A
- KORE N/A
- Fundamental
- Price
- ACET $0.59
- KORE $2.55
- Analyst Decision
- ACET Buy
- KORE Hold
- Analyst Count
- ACET 6
- KORE 1
- Target Price
- ACET $6.00
- KORE $2.50
- AVG Volume (30 Days)
- ACET 509.0K
- KORE 15.3K
- Earning Date
- ACET 05-13-2025
- KORE 05-14-2025
- Dividend Yield
- ACET N/A
- KORE N/A
- EPS Growth
- ACET N/A
- KORE N/A
- EPS
- ACET N/A
- KORE N/A
- Revenue
- ACET N/A
- KORE $285,229,000.00
- Revenue This Year
- ACET N/A
- KORE $3.89
- Revenue Next Year
- ACET N/A
- KORE $5.35
- P/E Ratio
- ACET N/A
- KORE N/A
- Revenue Growth
- ACET N/A
- KORE 7.01
- 52 Week Low
- ACET $0.45
- KORE $1.10
- 52 Week High
- ACET $1.87
- KORE $4.88
- Technical
- Relative Strength Index (RSI)
- ACET 42.27
- KORE 54.22
- Support Level
- ACET $0.51
- KORE $2.25
- Resistance Level
- ACET $0.62
- KORE $2.66
- Average True Range (ATR)
- ACET 0.06
- KORE 0.17
- MACD
- ACET 0.01
- KORE 0.02
- Stochastic Oscillator
- ACET 63.38
- KORE 80.36
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About KORE KORE Group Holdings Inc.
Kore Group Holdings Inc provides Internet of Things (IoT) solutions and services. In addition to providing critical services to customers globally, it enables them to manage, deploy, and scale their IoT applications and use cases. It offers connectivity services, location-based services, device solutions, and managed and professional services for the development and support of IoT technology for the Machine-to-Machine market. It derives revenue from IoT Connectivity services, IoT Solutions services, SIMs (IoT Connectivity), and IoT devices (IoT Solutions). Geographically, the company generates a majority of its revenue from the United States and the rest from other countries.